DGAP-News: Paketeria AG will take over 100% of INJEX PHARMA GMBH and the exclusive sales contracts of MMB GmbH for the INJEX, the needle free syringe, worth over Millions Euro
ID: 483496
Paketeria AG will take over 100% of INJEX PHARMA GMBH and the
exclusive sales contracts of MMB GmbH for the INJEX, the needle free
syringe, worth over Millions Euro
20.09.2011 / 13:57
---------------------------------------------------------------------
Paketeria AG will take over 100% of INJEX PHARMA GMBH and the exclusive
sales contracts of MMB GmbH for the INJEX, the needle free syringe, worth
over Millions Euro
Paketeria AG / ISIN:DE000A0STYL7
Berlin, 20. September 2011
The listed Paketeria AG agrees with MMB Medical Marketing Berlin GmbH to
acquire the remaining 80% after having already implanted 20% shares in
INJEX PHARMA GMBH . The supervisory board of Paketeria Ag approved the
takeover of INJEX PHARMA and is focusing on the distribution of the
needle-free system of the signed contract of MMB GmbH , in particular the
granting distribution rights to the Paketeria AG.
The business content of MMB GmbH, which is focused on sales and marketing
of needle free injection technology and the signed exclusive distributor
agreements worth over Millions Euros will be transferred as well.
The takeover of Injex Pharma and the transfer of business from MMB will be
performed in a capital increase by way of contribution in kind. The
evaluation will be appointed by an official auditor soon. The MMB GMBH
will act after the completion of the transaction as a pure holding company.
MMB GMBH and Paketeria Ag have agreed with the involvement of the
supervisory board to transfer shares of INJEX PHARMA to Paketeria AG at a
price of 3,20 Euro. These shares from the capital increase will also be
subject to a lock up
MMB staff will be transferred as soon as possible to INJEX /Paketeria AG.
INJEX PHARMA will act as the manufacturer and R&D Group in the future.
Sales and marketing for the innovative needle-free technology will be
performed by Paketeria AG.
The capital increase requires some judicial decisions. The evaluation
report must be approved by the court. The Annual Meeting of Paketeria AG
will be held on the 9th of December for final decisions. Invitations will
be sent six weeks before the meeting.
The board of management has informed the supervisory board that the auditor
will confirm an existing minimum equity capital of at least 500,000EUR this
week and that the German stock exchange will be informed immediately. This
will secure the listing on the open market
Kontakt:
Andy Rösch
Vorstand
Paketeria AG
Buckower Damm 114
12349 Berlin
Tel.: 030/53096768
andy.roesch@medical-marketing-berlin.com
www.injex.de
Dr. Ulrich Franz
Aufsichtsratsmitglied
Ulrich.franz@gmx.net
End of Corporate News
---------------------------------------------------------------------
20.09.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
139823 20.09.2011
Themen in dieser Pressemitteilung:
paketeria-ag-will-take-over-100-of-injex-pharma-gmbh-and-the-exclusive-sales-contracts-of-mmb-gmbh-for-the-injex
the-needle-free-syringe
worth-over-millions-euro
Unternehmensinformation / Kurzprofil:
Datum: 20.09.2011 - 13:57 Uhr
Sprache: Deutsch
News-ID 483496
Anzahl Zeichen: 3703
Kontakt-Informationen:
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 426 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Paketeria AG will take over 100% of INJEX PHARMA GMBH and the exclusive sales contracts of MMB GmbH for the INJEX, the needle free syringe, worth over Millions Euro"
steht unter der journalistisch-redaktionellen Verantwortung von
Paketeria AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
